Compare ANL & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANL | RGR |
|---|---|---|
| Founded | 2004 | 1949 |
| Country | Singapore | United States |
| Employees | N/A | 1780 |
| Industry | | Ordnance And Accessories |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 998.8M | 806.1M |
| IPO Year | 2022 | 1994 |
| Metric | ANL | RGR |
|---|---|---|
| Price | $10.80 | $50.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $29.50 | ★ $51.50 |
| AVG Volume (30 Days) | 268.1K | ★ 533.1K |
| Earning Date | 08-14-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | ★ $546,057,000.00 |
| Revenue This Year | $243.83 | $9.15 |
| Revenue Next Year | N/A | $0.47 |
| P/E Ratio | ★ N/A | $63.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $28.33 |
| 52 Week High | $17.25 | $54.00 |
| Indicator | ANL | RGR |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 60.26 |
| Support Level | $8.95 | $37.20 |
| Resistance Level | $11.90 | $50.84 |
| Average True Range (ATR) | 0.99 | 2.20 |
| MACD | 0.25 | 0.21 |
| Stochastic Oscillator | 72.55 | 63.98 |
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States, and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.